Emerging therapies and future directions in pulmonary arterial hypertension
V Gurtu, ED Michelakis - Canadian Journal of Cardiology, 2015 - Elsevier
Pulmonary arterial hypertension (PAH) is a complex obliterative vascular disease. It remains
deadly despite an explosion of basic research over the past 20 years that identified myriads
of potential therapeutic targets, few of which have been translated into early phase trials.
Despite the agreement over the past decade that its pathogenesis is based on an
antiapoptotic and proproliferative environment within the pulmonary arterial wall, and not
vasoconstriction, all the currently approved therapies were developed and tested in PAH …
deadly despite an explosion of basic research over the past 20 years that identified myriads
of potential therapeutic targets, few of which have been translated into early phase trials.
Despite the agreement over the past decade that its pathogenesis is based on an
antiapoptotic and proproliferative environment within the pulmonary arterial wall, and not
vasoconstriction, all the currently approved therapies were developed and tested in PAH …